Tissue microarray technology: principles, pitfalls and perspectives--lessons learned from hematological malignancies

Alexandar Tzankov; Philip Went; Annette Zimpfer; Stephan Dirnhofer

doi:10.1016/j.exger.2005.06.011

Tissue microarray technology: principles, pitfalls and perspectives--lessons learned from hematological malignancies

Exp Gerontol. 2005 Aug-Sep;40(8-9):737-44. doi: 10.1016/j.exger.2005.06.011.

Authors

Alexandar Tzankov¹, Philip Went, Annette Zimpfer, Stephan Dirnhofer

Affiliation

¹ The Institutes of Pathology, Medical University of Innsbruck, Muellerstr. 44, A-6020 Innsbruck, Austria. alexandar.tzankov@uibk.ac.at

PMID: 16125349
DOI: 10.1016/j.exger.2005.06.011

Abstract

Detection, validation and incorporation into clinical use of new diagnostic, prognostic and therapeutic molecular targets in modern medical science should be time- and cost-efficient. Here, we discuss the principles, advantages, disadvantages and possible pitfalls of tissue microarray (TMA) technology, a powerful tool for high throughput large-scale morphological in situ analysis of molecular targets. Based on recent observations from molecular profiling of hematological malignancies, we review potential TMA applications assessing molecular targets in large collectives of tissue specimens.

Publication types

Evaluation Study

MeSH terms

Animals
Biomarkers, Tumor / analysis*
Gene Expression Profiling*
Hematologic Neoplasms / genetics*
Humans
Molecular Probe Techniques
Neoplasm Proteins / analysis
Neoplasm Proteins / genetics*
Oligonucleotide Array Sequence Analysis*
Protein Array Analysis

Substances

Biomarkers, Tumor
Neoplasm Proteins